Elevance Health falls on profit forecast cut; rival insurers also decline
Updates
** Shares of health insurer Elevance Health ELV.N fall 11.9%to $437.65 premarket
** Co cuts 2024 adj. profit forecast to $33 per share, compared with previous estimate of $37.20; also missing analysts' estimates of $37.26 per share, as per data compiled by LSEG
** Reports Q3 adj. profit of $8.37 per share, missing estimates of $9.66 per share
** Reports Q3 medical loss ratio — the percentage of premiums spent on medical care — of 89.5% compared with analysts' estimates of 87.15%
** Shares of rival health insurers down between 1% and 12% premarket
** Centene CNC.N down 7.6%, CVS Health CVS.N down 1.4%, Humana HUM.N down 1.8%, Molina HealthcareMOH.N down 11.6%
** Baird analysts say ELV's "Q3 print is much worse than our base case scenario"; says results are "the perfect storm of Q3 underperformance"
** Up to last close, ELV up 5.4% YTD
Reporting by Sneha S K
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
